Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hojjat Ahmadzadehfar

Showing results (1-10 of 175) with videos related to

Pageof 18
Sort By:
Pharmaceuticals (Basel, Switzerland)|October 23, 2021
Combination Therapies with PRRTAnna Yordanova, Hojjat Ahmadzadehfar
PET Clinics|May 31, 2021
PET in the Era of Theranostics. PrefaceHojjat Ahmadzadehfar, Ali Gholamrezanezhad
EJNMMI Research|January 31, 2018
It is time to move forward into the era of TheranosticsHojjat Ahmadzadehfar, Markus Essler
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 15, 2018
Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing <sup>177</sup>Lu-PSMA TherapyHojjat Ahmadzadehfar, Markus Essler
World Journal of Nuclear Medicine|January 15, 2020
<sup>177</sup>Lu-DOTATATE and <sup>177</sup>Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatmentMajid Assadi, Hojjat Ahmadzadehfar
European Urology|June 2, 2019
Reply to Bingzhi Wang, Huan Deng, and Lan Cao's Letter to the Editor re: Hojjat Ahmadzadehfar, Markus Essler. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.028: Despite its Slightly Limited Specificity, Prostate-specific Membrane Antigen Imaging is Still a Game Changer in Prostate Cancer Diagnosis and Therapy PlanningHojjat Ahmadzadehfar, Markus Essler
Clinical Nuclear Medicine|September 21, 2020
Re: Medical Event: Accidental Oral Administration of 177Lu-PSMA to a Patient With HyperthyroidismKambiz Rahbar, Hojjat Ahmadzadehfar
European Urology|March 6, 2019
Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy PlanningHojjat Ahmadzadehfar, Markus Essler
Deutsches Arzteblatt International|November 18, 2021
Utility of PSMA-PET imagingHojjat Ahmadzadehfar, Hans Jürgen Biersack
European Journal of Nuclear Medicine and Molecular Imaging|November 23, 2017
<sup>177</sup>Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?Kambiz Rahbar, Hojjat Ahmadzadehfar, Martin Boegemann
Pageof 18

Showing results (1-10 of 175) with videos related to

Sort By:
Pageof 18
Pharmaceuticals (Basel, Switzerland)|October 23, 2021
Combination Therapies with PRRTAnna Yordanova, Hojjat Ahmadzadehfar
PET Clinics|May 31, 2021
PET in the Era of Theranostics. PrefaceHojjat Ahmadzadehfar, Ali Gholamrezanezhad
EJNMMI Research|January 31, 2018
It is time to move forward into the era of TheranosticsHojjat Ahmadzadehfar, Markus Essler
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 15, 2018
Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing <sup>177</sup>Lu-PSMA TherapyHojjat Ahmadzadehfar, Markus Essler
World Journal of Nuclear Medicine|January 15, 2020
<sup>177</sup>Lu-DOTATATE and <sup>177</sup>Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatmentMajid Assadi, Hojjat Ahmadzadehfar
European Urology|June 2, 2019
Reply to Bingzhi Wang, Huan Deng, and Lan Cao's Letter to the Editor re: Hojjat Ahmadzadehfar, Markus Essler. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.028: Despite its Slightly Limited Specificity, Prostate-specific Membrane Antigen Imaging is Still a Game Changer in Prostate Cancer Diagnosis and Therapy PlanningHojjat Ahmadzadehfar, Markus Essler
Clinical Nuclear Medicine|September 21, 2020
Re: Medical Event: Accidental Oral Administration of 177Lu-PSMA to a Patient With HyperthyroidismKambiz Rahbar, Hojjat Ahmadzadehfar
European Urology|March 6, 2019
Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy PlanningHojjat Ahmadzadehfar, Markus Essler
Deutsches Arzteblatt International|November 18, 2021
Utility of PSMA-PET imagingHojjat Ahmadzadehfar, Hans Jürgen Biersack
European Journal of Nuclear Medicine and Molecular Imaging|November 23, 2017
<sup>177</sup>Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?Kambiz Rahbar, Hojjat Ahmadzadehfar, Martin Boegemann
Pageof 18